Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.52 |
| ▸ | CTSB | P07858 | 2/20 | 0.47 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.39 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16369984 | 1.00 | L3MBTL1 (0.52) | L3MBTL1CTSBPPARANPSR1ALDH1A1 | |
| SCHEMBL16369967 | 0.90 | L3MBTL1 (0.55) | L3MBTL1CTSBPPARANPSR1ALDH1A1 | |
| SCHEMBL16369968 | 0.90 | L3MBTL1 (0.55) | L3MBTL1CTSBPPARANPSR1ALDH1A1 | |
| SCHEMBL4344800 | 0.87 | L3MBTL1 (0.59) | L3MBTL1CTSBPPARANPSR1ALDH1A1 | |
| SCHEMBL19388775 | 0.84 | L3MBTL1 (0.45) | L3MBTL1CTSBPPARANPSR1ALDH1A1 | |
| SCHEMBL16370655 | 0.84 | L3MBTL1 (0.45) | L3MBTL1CTSBPPARANPSR1ALDH1A1 | |
| SCHEMBL17586866 | 0.83 | ALDH1A1 (0.46) | L3MBTL1CTSBALDH1A1LMNACTSS | |
| SCHEMBL16407796 | 0.81 | L3MBTL1 (0.43) | L3MBTL1CTSBPPARANPSR1LMNA | |
| SCHEMBL16993182 | 0.76 | L3MBTL1 (0.62) | L3MBTL1CTSBPPARANPSR1ALDH1A1 | |
| SCHEMBL22398838 | 0.76 | L3MBTL1 (0.47) | L3MBTL1CTSBNPSR1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3019196-B1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-06 | — | — | EP | disclosed |
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-06-09 | — | — | US | disclosed |
| EP-3019196-A1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-05-18 | — | — | EP | disclosed |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2015-01-22 | — | — | US | disclosed |
| WO-2015005901-A1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | L3MBTL1 2254/4885CTSB 1519/4885PPARA 3278/4885 |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | L3MBTL1 2254/4885CTSB 1519/4885PPARA 3278/4885 |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | L3MBTL1 1789/4885CTSB 1748/4885PPARA 3436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.